Health Care·Biotechnology·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.40 | N/A | -3.09% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.40 | N/A | -3.09% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter. They emphasized their commitment to ongoing development efforts.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current financial results.
BioCryst Pharmaceuticals reported a wider-than-expected loss per share, leading to a 3.93% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term outlook. The market reaction reflects uncertainty regarding their financial health and future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ENTERPRISE PRODS PAR
May 2, 2022